Lim, Luigi and Machingura, Abigirl and Taye, Mekdes and Pe, Madeline and Coens, Corneel and Martinelli, Francesca and Alanya, Ahu and Antunes, Stephanie and Tu, Dongsheng and Basch, Ethan and Ringash, Jolie and Brandberg, Yvonne and Groenvold, Mogens and Eggermont, Alexander and Cardoso, Fatima and Van Meerbeeck, Jan and Koller, Michael and van der Graaf, Winette T. A. and Taphoorn, Martin J. B. and Koekkoek, Johan A. F. and Reijneveld, Jaap C. and Soffietti, Riccardo and Velikova, Galina and Bottomley, Andrew and Flechtner, Henning and Musoro, Jammbe (2025) Prognostic value of baseline EORTC QLQ-C30 scores for overall survival across 46 clinical trials covering 17 cancer types: a validation study. ECLINICALMEDICINE, 82: 103153. ISSN , 2589-5370
Full text not available from this repository. (Request a copy)Abstract
Background A pooled data analysis by Quinten et al. (2009) found three European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) health-related quality of life (HRQoL) scales to be prognostic for survival: physical functioning, pain and appetite loss. This study aims to replicate these findings in an independent data set comprising a broader cancer population. Methods Data were obtained from 46 clinical trials across three cancer research networks conducted between 1996 and 2013 that assessed HRQoL using the EORTC QLQ-C30. A stratified Cox proportional hazards model was employed to assess the prognostic significance of baseline QLQ-C30 scale scores on overall survival, adjusting for socio-demographic and clinical variables. Stepwise model selection was done at 5% significance level. Model stability and prognostic accuracy were evaluated via bootstrapping and the C index respectively. Findings Data from 16,210 patients reporting HRQoL at baseline, spanning 17 cancer types, was used. The stratified multivariable model confirmed that better physical functioning (hazard ratio [HR], 0.94; 95% confidence interval [CI], 0.93-0.96), lower pain (HR, 1.02; 95% CI, 1.01-1.03), and appetite loss (HR, 1.04; 95% CI, 1.03-1.05) were significantly associated with survival. Additionally, global health status/QoL, dyspnoea, emotional and cognitive functioning were found to be prognostic for survival. This final model, encompassing sociodemographic, clinical, and HRQoL variables, achieved a corrected C index of 0.74, marking a 48% enhancement in discriminatory ability. Bootstrap evaluation indicated no major instability issues. Interpretation These results support previous findings that baseline physical functioning, pain, and appetite loss scores, along with four other scales from the EORTC QLQ-C30, predict survival in cancer patients. Funding EORTC Quality of Life Group. Copyright (c) 2025 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | QUALITY-OF-LIFE; PATIENT-REPORTED OUTCOMES; PREDICTING SURVIVAL; MODELS; TUMOR; WOMEN; Cancer clinical trial; Health-related quality of life; Survival; Prognostic factor analysis; Validation; Pooled data |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Zentren des Universitätsklinikums Regensburg > Zentrum für Klinische Studien |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 31 Mar 2026 06:25 |
| Last Modified: | 31 Mar 2026 06:25 |
| URI: | https://pred.uni-regensburg.de/id/eprint/67900 |
Actions (login required)
 |
View Item |
